Open AccessS771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
Author(s) -
Séverine Vermeire,
Silvio Danese,
Wen Zhou,
Aileen L. Pangan,
Susan Greenbloom,
Geert DʼHaens,
Julián Panés,
Pascal Juillerat,
James O. Lindsay,
Edward V. Loftus,
William J. Sandborn,
Walter Reinisch,
Yuri Sanchez-Gonzalez,
Bidan Huang,
Wangang Xian,
Jianzhong Liu,
Michael Weinreich,
Remo Panaccione
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776616.76910.14
Subject(s) - medicine , clinical endpoint , placebo , ulcerative colitis , population , gastroenterology , randomized controlled trial , adverse effect , clinical trial , surrogate endpoint , phases of clinical research , surgery , disease , alternative medicine , environmental health , pathology